On-Q-ity

On-Q-ity was a biotechnology firm established in 2009 through the amalgamation of Cellective Dx and DNA Repair Inc. (DNAR), launching with a significant $26 million Series A funding round. The company was founded by Mara Aspinall, a seasoned executive with a notable tenure at Genzyme Corporation. Aspinall's background in leading and expanding Genzyme's genetics division underscored the initial promise of On-Q-ity's mission.

The company focused on the oncology diagnostics market, aiming to personalize cancer treatment. Its business strategy was centered on two primary technology platforms: DNA repair pathway biomarkers to forecast drug efficacy and a proprietary microfluidic chip for capturing and analyzing circulating tumor cells (CTCs) from a patient's bloodstream. This dual approach was intended to provide oncologists with a comprehensive view for making treatment decisions and monitoring patient progress in a minimally invasive manner. The target clients were primarily pharmaceutical companies for clinical trial support and oncologists for clinical practice.

On-Q-ity's core product was a diagnostic service based on its technologies. The CTC platform, in particular, was designed to isolate rare tumor cells from blood samples, allowing for their enumeration and molecular characterization. This service offered the benefit of a "liquid biopsy," a less invasive alternative to tissue biopsies for monitoring tumor changes and treatment response over time. A partnership with LabCorp was established to market this platform for research purposes.

Despite its promising start, On-Q-ity faced substantial hurdles. Clinical trials for its DNA repair biomarkers yielded disappointing results, consuming a large portion of its initial capital. The CTC platform encountered unforeseen technical difficulties that required a costly and time-consuming redevelopment. These technical setbacks were compounded by significant management instability, with frequent changes in key executive roles. By early 2012, the firm had depleted its funds, necessitating a small Series B round to continue operations while seeking a strategic partner. Ultimately, the search for an acquirer was unsuccessful, and with cash reserves once again depleted, the board decided to wind down operations in late 2012. The final sale of intellectual property was completed by April 2013, marking the end of the company.

Keywords: cancer diagnostics, circulating tumor cells, CTC, liquid biopsy, DNA repair biomarkers, personalized medicine, oncology, molecular diagnostics, Mara Aspinall, Cellective Dx, DNAR, microfluidics, cancer treatment monitoring, diagnostic failure, biotech shutdown, Atlas Ventures, Mohr Davidow Ventures, Waltham biotech